<SEC-DOCUMENT>0001209191-22-022616.txt : 20220404
<SEC-HEADER>0001209191-22-022616.hdr.sgml : 20220404
<ACCEPTANCE-DATETIME>20220404175826
ACCESSION NUMBER:		0001209191-22-022616
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220404
DATE AS OF CHANGE:		20220404

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			RIEFLIN WILLIAM JL
		CENTRAL INDEX KEY:			0001182471

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38997
		FILM NUMBER:		22804217

	MAIL ADDRESS:	
		STREET 1:		NGM BIOPHARMACEUTICALS, INC.
		STREET 2:		333 OYSTER POINT BLVD.
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RAPT Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001673772
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473313701
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 489-9000

	MAIL ADDRESS:	
		STREET 1:		561 ECCLES AVENUE
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLX Bio, Inc.
		DATE OF NAME CHANGE:	20160504
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>doc4.xml
<DESCRIPTION>FORM 4 SUBMISSION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-03-31</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001673772</issuerCik>
        <issuerName>RAPT Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>RAPT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001182471</rptOwnerCik>
            <rptOwnerName>RIEFLIN WILLIAM JL</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O RAPT THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>561 ECCLES AVENUE</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>21.99</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2022-03-31</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness>
                <value></value>
            </transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>5207</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>16.80</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2032-03-30</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>5207</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5207</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2022 with the first installment vesting on March 31, 2022, provided that the reporting person is in service as a director on each such vesting date.</footnote>
        <footnote id="F2">This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of $87,500.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Rodney Young, Attorney-in-Fact for William Rieflin</signatureName>
        <signatureDate>2022-04-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
